Epilepsy Outcome at Four Years in a Randomized Clinical Trial Comparing Oral Prednisolone and Intramuscular ACTH in West Syndrome.
Administration, Oral
Adrenocorticotropic Hormone
/ administration & dosage
Child, Preschool
Female
Follow-Up Studies
Glucocorticoids
/ administration & dosage
Humans
Infant
Injections, Intramuscular
Male
Outcome Assessment, Health Care
Prednisolone
/ administration & dosage
Spasms, Infantile
/ drug therapy
ACTH
Epilepsy
Epileptic spasms
Infantile spasms
Outcome
Prednisolone
West syndrome
Journal
Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
14
07
2020
revised:
01
01
2021
accepted:
24
01
2021
pubmed:
10
4
2021
medline:
27
1
2022
entrez:
9
4
2021
Statut:
ppublish
Résumé
This article explores the role of initial treatment on control of spasms and other epilepsies at four years in children previously treated for West syndrome. The Sri Lanka Infantile Spasm Study is a prospective clinical trial evaluating response to intra-muscular adrenocorticotropic hormone (ACTH) versus oral prednisolone. A previous report documented response through age 12 months. This article provides four-year follow-up data. At age four years, 65 of the original 97 were available for follow-up; another 13 had died, and 19 moved and could not be contacted. Of the 65 children, 37 (57%) continued to have seizures and 28 were seizure free. In the 37 children with ongoing epilepsy, 32.4% continued to have spasms, either alone or in combination with other seizure types. The epilepsy types seen in these children were focal epilepsy (59.4%), mixed focal and generalized epilepsy (24%), generalized epilepsy only (10.8%), and uncertain (5%). The majority of those still having epilepsy (66.7%) were controlled on medication. There was no significant difference in the rate of epilepsy or spasms or their control by medication between those treated with ACTH or oral prednisolone. Spasm control at day 14 did not influence the four-year spasm or epilepsy outcome. A majority of children diagnosed with West syndrome continued to have seizures at age four years, although most were controlled on antiseizure medication. The long-term risk of developing epilepsy or its control was the same, regardless of whether ACTH or prednisolone was initially used as treatment.
Sections du résumé
BACKGROUND
This article explores the role of initial treatment on control of spasms and other epilepsies at four years in children previously treated for West syndrome.
METHODS
The Sri Lanka Infantile Spasm Study is a prospective clinical trial evaluating response to intra-muscular adrenocorticotropic hormone (ACTH) versus oral prednisolone. A previous report documented response through age 12 months. This article provides four-year follow-up data.
RESULTS
At age four years, 65 of the original 97 were available for follow-up; another 13 had died, and 19 moved and could not be contacted. Of the 65 children, 37 (57%) continued to have seizures and 28 were seizure free. In the 37 children with ongoing epilepsy, 32.4% continued to have spasms, either alone or in combination with other seizure types. The epilepsy types seen in these children were focal epilepsy (59.4%), mixed focal and generalized epilepsy (24%), generalized epilepsy only (10.8%), and uncertain (5%). The majority of those still having epilepsy (66.7%) were controlled on medication. There was no significant difference in the rate of epilepsy or spasms or their control by medication between those treated with ACTH or oral prednisolone. Spasm control at day 14 did not influence the four-year spasm or epilepsy outcome.
CONCLUSIONS
A majority of children diagnosed with West syndrome continued to have seizures at age four years, although most were controlled on antiseizure medication. The long-term risk of developing epilepsy or its control was the same, regardless of whether ACTH or prednisolone was initially used as treatment.
Identifiants
pubmed: 33836476
pii: S0887-8994(21)00009-6
doi: 10.1016/j.pediatrneurol.2021.01.008
pii:
doi:
Substances chimiques
Glucocorticoids
0
Adrenocorticotropic Hormone
9002-60-2
Prednisolone
9PHQ9Y1OLM
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
22-26Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.